Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 416Lymphoma 406Lymphoma, Non-Hodgkin 344Leukemia, Lymphocytic, Chronic, B-Cell 313Lymphoma, Follicular 301Lymphoma, Mantle-Cell 226Lymphoma, B-Cell, Marginal Zone 161Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 85Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Hematologic Neoplasms 22Dendritic Cell Sarcoma, Interdigitating 22Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Hematologic Diseases 13Lymphoproliferative Disorders 12

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Off-Label Use × Rituximab × Clear all
NCT02654379 2018-04-09

Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Hoffmann-La Roche

Completed
1,408 enrolled

Off-Label Use

Data powered by HemOnc (CC BY 4.0) Colophon âš¡